CFO
SRPT icon

CVA Family Office’s Sarepta Therapeutics SRPT Stock Holding History

CVA Family Office’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$180 Hold
10
– – ﹤0.01% 1773
2026
Q1 		$218 Buy
+10
New +$194 ﹤0.01% 1807
2025
Q3 		– Sell
-13
Closed -$222 – 1340
2025
Q2 		$222 Buy
13
+7
+117% +$299 ﹤0.01% 1268
2025
Q1 		$383 Buy
+6
New +$632 ﹤0.01% 1362

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

CVA Family Office's SRPT Position: Q2 2026 in Review

CVA Family Office held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 10 shares worth $180. The position accounts for ﹤0.01% of the portfolio, ranked #1773.

CVA Family Office first reported a position in SRPT in Q1 2025 and has held it in 4 quarters since. The position peaked at $383 in Q1 2025. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • CVA Family Office held 10 shares of Sarepta Therapeutics worth $180 as of Q2 2026.
  • CVA Family Office left its Sarepta Therapeutics share count unchanged in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1773 holding.
  • CVA Family Office first reported a position in Sarepta Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • CVA Family Office's Sarepta Therapeutics position peaked at $383 in Q1 2025.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.